{
    "ticker": "XENE",
    "name": "Xenon Pharmaceuticals Inc.",
    "description": "Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with rare neurological disorders and other diseases. Founded in 2003 and headquartered in Burnaby, British Columbia, the company leverages its proprietary Xenon Discovery Platform to identify and develop medicines that target the underlying genetic causes of diseases. Xenon's pipeline includes a variety of programs, such as XEN1101, a treatment for focal epilepsy, which is currently in late-stage clinical trials. The company is also exploring additional therapeutic areas, including pain management and other central nervous system disorders. With a team of experienced scientists and leaders in drug development, Xenon is committed to delivering life-changing therapies to patients with unmet medical needs. The company's dedication to innovation is complemented by strategic partnerships with other biopharmaceutical companies, enhancing its ability to advance its drug candidates through clinical development. Xenon's mission is to bring hope to patients and their families by transforming the way rare neurological disorders are treated.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Burnaby, British Columbia, Canada",
    "founded": "2003",
    "website": "https://www.xenon-pharma.com",
    "ceo": "Simon Haworth",
    "social_media": {
        "twitter": "https://twitter.com/XenonPharma",
        "linkedin": "https://www.linkedin.com/company/xenon-pharmaceuticals/"
    },
    "investor_relations": "https://investors.xenon-pharma.com",
    "key_executives": [
        {
            "name": "Simon Haworth",
            "position": "CEO"
        },
        {
            "name": "David R. Stover",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Neurology",
            "products": [
                "XEN1101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Xenon Pharmaceuticals Inc. | Innovative Neurological Treatments",
        "meta_description": "Learn about Xenon Pharmaceuticals Inc., a leading biopharmaceutical company developing therapies for rare neurological disorders. Discover our innovative pipeline and commitment to patient care.",
        "keywords": [
            "Xenon Pharmaceuticals",
            "Neurology",
            "Biotechnology",
            "XEN1101",
            "Rare Diseases",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does Xenon Pharmaceuticals do?",
            "answer": "Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative treatments for rare neurological disorders."
        },
        {
            "question": "Who is the CEO of Xenon Pharmaceuticals?",
            "answer": "Simon Haworth is the CEO of Xenon Pharmaceuticals Inc."
        },
        {
            "question": "Where is Xenon Pharmaceuticals headquartered?",
            "answer": "Xenon Pharmaceuticals is headquartered in Burnaby, British Columbia, Canada."
        },
        {
            "question": "What are Xenon's main products?",
            "answer": "Xenon's main product in development is XEN1101, aimed at treating focal epilepsy."
        },
        {
            "question": "When was Xenon Pharmaceuticals founded?",
            "answer": "Xenon Pharmaceuticals was founded in 2003."
        }
    ],
    "competitors": [
        "VRTX",
        "NVS",
        "ABBV",
        "BIIB"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "MRNA"
    ]
}